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CBackground: The aim of this study was to compare quality-adjusted life
expectancy (QALE) for patients with rheumatoid arthritis generated
from three generic health-related quality-of-life instruments.
Methods: Patients from 11 Danish rheumatology outpatient clinics
were asked to report current health status using the EuroQol five-di-
mensional questionnaire (EQ-5D), 15D, and six-dimensional health
state short form (derived fromSF-12) (SF-6D) instruments. Clinical staff
provided data on current disease status (C-reactive protein andDisease
Activity Score that involves clinical assessment of 28 joints). National
mortality data were retrieved from Statistics Denmark. For each of the
three instruments, mean index scores were estimated by gender and
5-year age groups. Partial QALE was estimated for the age interval 30 to
79 years for different subsamples. Results: Although the three quality-
of-life index scores were highly correlated, there were statistically sig-
nificant differences between the average index scores from the three
instruments. The 15D provided the highest index score and SF-6D the
lowest score. For a 30-year-old patient, the partial QALE ranged from O
o rep
ealt
ark.
al So
doi:10.1016/j.jval.2011.09.0107.9 quality-adjusted life-years using the SF-6D to 45.6 quality-adjusted
ife-years using the 15D. The QALE for men and women differed by
.2%, 4.0%, and 5.3% when the calculation was based on EQ-5D, SF-6D,
nd 15D index scores, respectively. The largest differences were ob-
erved when patients were grouped by functional status (Health As-
essment Questionnaire score), where the EQ-5D showed a 50% differ-
nce in index score between the best and worst functional group while
he SF-6D and 15D showed smaller differences (32% and 14%,
espectively). Discussion: This analysis has shown the difference in
ALE estimates related to different instruments. The study empha-
izes that unless outcome studies use the same instruments and scor-
ng algorithms, the results will not be directly comparable.
eywords: EQ-5D, 15D, SF-6D, quality-adjusted life expectancies, rheu-
atoid arthritis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Quality-adjusted life expectancy (QALE) is a health measure that
takes both the survival andhealth-related quality of life (HRQoL) of
an individual into account. The conceptwas pioneered in the early
1970s and has since been applied in epidemiological and health
economic research [1] and has been used to describe the lifetime
impact from different diseases or unhealthy behavior (e.g., [2–4])
and as benefit from medical technology [5]. QALE is achieved by
weighting the lifetime survival function by the mean utility of
quality of life for each time period and then summing the result
across the person’s lifetime.
Most health economics textbooks denote this approach as the
“quality-adjusted life-year (QALY) approach” and apply the QALY
term to denote both the health measure and the counting unit.
When the term QALE is used to denote the health measure, a
stronger emphasis is placed on the lifetime perspective and on the
uncertainty of future events, and there is a clear difference be-
tween the health measure (QALE) and the counting unit (QALY).
With this terminology, economic evaluations can use QALE to ex-
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1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.press the health benefit as the additional number of QALYs pro-
duced by a technology [6].
The QALY approach has become standard in most economic
evaluations [7] although guidelines continue to be refined [8]. The
UK National Institute for Clinical Excellence recommends that
cost-effectiveness analyses of health interventions present pa-
tient-related outcome in terms of QALY whenever possible [9].
National Institute for Clinical Excellence suggests the use of the
generic utility-based health outcome measure EuroQol five-di-
mensional (EQ-5D) questionnaire (EQ-5D) to count the QALY gain
[10]. The EQ-5D is easy to understand, simple to administer, avail-
able in many language versions, and has been widely used as a
measure of outcome in both clinical and population studies [11].
Other generic health outcome instruments exist, however, that
can also generate a single index score for HRQoL [12]. Guidelines
regarding the choice of instrument for collecting data for QALE
calculations are available (e.g., [13]), as are numerous examples of
validity tests of the various instruments in different patient
groups (e.g., [14]).
The aim of this study was to explore the difference in QALE by
using three different HRQoL instruments. We performed a cross-
ort.
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335V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 3 4 – 3 3 9sectional study involving patients with rheumatoid arthritis (RA),
in which patients described their current HRQoL on three generic
utility-based instruments: EQ-5D, 15D, and 12-item short-form
health survey (SF-12). These self-report data were then combined
with national mortality data to produce QALE estimates.
Materials and methods
Patients and data collection
A cross-sectional study involving 11 Danish rheumatology out-
patient clinics was undertaken between July 2006 and July 2007
[14,15]. Patients with a diagnosis of RA as defined by the Amer-
ican College of Rheumatology 1987 criteria [16] were eligible for
inclusion. No exclusion criteria were specified. Patients were
asked to complete a questionnaire during a routine visit to the
clinic, and their clinician completed a supplementary question-
naire at the same visit.
The patient questionnaire included the Danish versions of EQ-
5D, 15D, and SF-12 version 2 and the functional measure Health
Assessment Questionnaire (HAQ). The clinicians provided data on
the patient’s clinical status in terms of serum C-reactive protein
(CRP) levels and disease activity asmeasured by the DAS28 instru-
ment (Disease Activity Score that involves clinical assessment of
28 joints [www.das-score.nl]). CRP levelswere used to classify clin-
ical disease status as normal (CRP  10 mg/L) or high (CRP  10
g/L). Disease activitywas used to classify patients as either being
n remission (DAS28  2.6) or having active disease (DAS28  2.6).
The HAQ is a measure of functional disability in RA [17,18]. It
omprises 20 questions in eight categories of functioning
dressing, arising, eating, walking, hygiene, reach, grip, and
sual activities), and the response options range from 0 (no
ifficulty) to 3 (unable to do). The highest scores of each dimen-
ion are summed and divided by 8, resulting in a total score
HAQ score) that ranges from 0 (no difficulty) to 3 (unable to do)
17]. We used the Danish HAQ translation [19] and computed a
otal score without including items on aids/help from other peo-
le. The resulting HAQ score was used to form three groups of
unctional disability (HAQ  1, HAQ  1–2, HAQ  2).
The EQ-5D is a generic utility-based health status instru-
ent comprising five dimensions of health (mobility, self-care,
sual activities, pain/discomfort, anxiety/depression), which in
he original version are each divided into three levels of severity
20,21]. In this study, we used five levels of severity in each
imension, as suggested by Kind [22] and subsequently tested
Table 1 – Characteristics of the sample.
30–39
(n  170)
40–49
(n  373)
n % n %
Women 144 85 301 81
HAQ  1 140 82 307 82
HAQ  1–2 26 15 60 16
HAQ  2 4 2 6 2
In DAS28 remission 69 41 146 39
With high CRP 47 28 81 22
With missing EQ-5D items 8 5 12 3
With missing 15D items 29 17 55 15
With missing SF-6D items 14 8 33 9
CRP, C-reactive protein; DAS28, Disease Activity Score that involves
questionnaire; HAQ, Health Assessment Questionnaire; SF-6D, six-diy Janssen and colleagues [23,24]. Patients were asked to de-cribe their health state as of “today.” The recommended Dan-
sh scoring algorithm was applied to calculate an index score,
ith 0 denoting death and 1 denoting perfect health [25,26]. This
lgorithm provided scores ranging from 1.0 to 0.624. The
Q-5D instrument includes health states worse than death and
ssigns to these values lower than 0 (negative values). The five
evels were scored by using straight-line interpolation of the
alues for the three levels.
The 15D is a generic utility-based instrument for measuring
RQoL among adults (age 16 years) and comprises 15 dimen-
ions: mobility, vision, hearing, breathing, sleeping, eating,
peech, elimination, usual activities, mental function, discom-
ort and symptoms, depression, distress, vitality, and sexual
ctivity [27]. The respondents describe each dimension using
ve ordinal levels. The Danish set of preference weights was
sed to generate the 15D score index on a 0 to 1 scale [28]. The
anish algorithm provided scores ranging from 1.0 to 0.160.
The SF-12 is a generic health status instrument covering
oth physical and mental aspects of health [29,30]. The Danish
-week recall, version 2 was used. Six-dimensional health state
hort form (SF-6D) is a health status classification system that
an be generated from the SF-12 responses. It is composed of six
ultilevel dimensions: physical functioning, role limitations,
ocial functioning, pain, mental health, and vitality. A scoring
rogram has been developed to transform the SF-12 responses
o a single index score; the revised Brazier algorithm was used
ere to score the SF-12 data into the score index on a 0 to 1 scale
31,32]. The algorithm provided scores ranging from 1.0 to 0.345.
The characteristics of the sample are presented in Table 1.
Mortality data
We obtained population-based survival data from Statistics
Denmark based on national mortality data from 2004 to 2007.
The age- and sex-related survival probability was averaged for
men and women and aggregated into 5-year age groups. The
survival probability was calculated from 30 years of age in
5-year age intervals.
Analysis
A total of 3704 patients were contacted, of whom 548 never returned
the questionnaire. In this analysis, we excluded patients with RA
who were younger than 30 years (n 89) or older than 79 years (n
267) because of small numbers in these age groups. Missing items
were replaced with median item scores for respondents with one
Age group
50–59
 681)
60–69
(n  840)
70–79
(n  436)
All
(n  2500)
% n % n % n %
76 599 71 300 69 1864 75
74 605 72 287 66 1845 74
22 190 23 128 29 557 22
3 45 5 21 5 98 4
39 340 40 159 36 981 39
25 256 30 167 38 722 29
4 74 9 55 13 174 7
20 273 33 284 65 775 31
14 206 25 145 33 495 20
al assessment of 28 joints; EQ-5D, EuroQol five-dimensional (EQ-5D)
ional health state short form (derived from SF-12).(n
n
520
506
153
22
267
171
25
134
97
clinicitem missing on the EQ-5D (n  174) or on the SF-6D (n  370) and
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336 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 3 4 – 3 3 9with three or fewer missing items on the 15D (n  561). The sample
vailable for analysis consisted of 2500 respondents, of which 1640
66%) had completed all items on the three instruments.
For each of the three instruments, we conducted univariate
nalysis on the whole sample and estimated average index scores
or each gender and 5-year age group. Paired t-tests were used to
est the difference in mean index scores provided by the three
nstruments.We assessed the correlation between the three index
cores graphically and by calculating Pearson’s product–moment
orrelation coefficients.
To estimate health status index scores in 5-year age groups, we
sed ordinary least squares regressions, with the index scores as
xplained variables and dummy variables for 5-year age groups as
xplanatory variables. We interpreted the estimated parameters
s the average index score for the age group. The QALE was calcu-
ated as the sum of the products of the index score for the relevant
ge group and the probability of survival in the age group.
The method used does not provide estimates for individual
atients or for standard deviations. On the basis of estimated
ean parameters and covariance derived from the regression
odel, however, we employed the Krinsky–Robb procedure
33,34], in which random draws (here 10,000 draws) from an asymp-
otic normal distribution of the parameter estimates were collected
nd used in the calculation of individual QALE. On the basis of these
imulations, we estimated 95% confidence intervals. These simu-
atedconfidence intervalsdonot includeuncertainties relating to the
urvival probability, which was assumed to be deterministic.
We used stratified analyses to compare the calculated QALE for
ubgroups of patients. We performed separate analysis for male
nd female patients, patients with normal and elevated CRP lev-
ls, patients with three levels of HAQ scores (HAQ 1, HAQ 1–2,
HAQ  2), and patients with or without DAS28 remission. In addi-
ion, we conducted a sensitivity analysis that included only those
espondents who had provided answers on all items of the three
nstruments (n  1640).
Results
The three generic instruments produced different average index
scores for HRQoL (Table 2). The 15D instrument produced an av-
erage score that was 0.11 higher (on a 0–1 scale) (P 0.01)—that is,
a 15% higher score—than the EQ-5D score. The SF-6D produced an
average score that was 0.03 lower (P  0.01) than the EQ-5D score
(i.e., a 4% lower score). Judging by the standard deviations, the
precision of the mean scores was best for the 15D and poorest for
the EQ-5D. The skewness (EQ-5D 1.38; 15D 0.58; SF-6D 0.15)
ndicated longer left-hand tails for EQ-5D and 15D, whereas the
F-6D showed a small right-hand tail. Judging by the kurtosis
EQ-5D 7.73; 15D 2.98; SF-6D 2.48), the relatively large standard
eviation of the EQ-5D was the result of infrequent extreme devi-
Table 2 – Observed HRQoL scores from EQ-5D, 15D, and
SF-6D.
n Mean SD p25 p50 p75 Min Max
EQ-5D 2500 0.721 0.167 0.660 0.747 0.821 0.624 1.000
15D 2500 0.832 0.113 0.742 0.849 0.922 0.438 1.000
SF-6D 2500 0.693 0.136 0.594 0.681 0.782 0.345 1.000
Note: Paired t test comparing mean EQ-5D and 15D index: t  37.9;
P  0.01; mean EQ-5D and SF-6D index: t  11.0; P  0.01.
EQ-5D, EuroQol five-dimensional (EQ-5D) questionnaire; HRQoL,
health-related quality of life; SF-6D, six-dimensional health state
short form (derived from SF-36).tions. Full health (ceiling effect) was reported by 209 patients on
he EQ-5D, 113 on the 15D, and 54 on the SF-6D.
The age- and sex-stratified index scores are presented in Table
and Figure 1. The 15D produced consistently higher scores than
id the other two instruments, and the SF-6D index scores were
ignificantly lower than the EQ-5D scores in age groups older than
5 years. The age gradient wasmuch stronger for 15D (0.0026 per
ear of age) in comparison to SF-6D (0.0007) and EQ-5D (0.0003),
hich is also clear from Figure 1.
The correlation between the three instruments is shown under
igure 2, as the Pearson’s product–moment correlation coeffi-
ients. The index scores were moderately correlated, with Pear-
on’s correlation coefficients over 0.57. The scatter plots in Figure
suggest that an assumption about a linear relationship between
he instruments is not unreasonable. Regression analyses of the
Fig. 1 – Association between EQ-5D, 15D, and SF-6D index
score and age (n=2500). Estimated correlation coefficients:
Table 3 – Age- and sex-related mean index scores for
EQ-5D, 15D, and SF-6D.
Gender and age n EQ-5D 15D SF-6D
Male
30–34 12 0.793 0.91 0.742
35–39 14 0.782 0.908 0.765
40–44 32 0.746 0.872 0.704
45–49 40 0.762 0.884 0.737
50–54 63 0.746 0.872 0.729
55–59 98 0.738 0.858 0.709
60–64 114 0.738 0.848 0.736
65–69 127 0.759 0.852 0.732
70–74 82 0.736 0.823 0.712
75–79 54 0.760 0.729 0.699
Female
30–34 59 0.727 0.858 0.708
35–39 85 0.757 0.868 0.728
40–44 137 0.715 0.855 0.704
45–49 164 0.701 0.848 0.679
50–54 224 0.715 0.842 0.678
55–59 296 0.701 0.842 0.678
60–64 325 0.722 0.843 0.687
65–69 274 0.702 0.821 0.675
70–74 177 0.713 0.797 0.684
75–79 123 0.694 0.687 0.645
EQ-5D, EuroQol five-dimensional (EQ-5D) questionnaire; SF-6D, six-
dimensional health state short form (derived from SF-36).EQ-5D - 15D: 0.57; EQ-5D - SF-6D: 0.72; 15D - SF-6D: 0.61.
337V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 3 4 – 3 3 9relationship between the index scores indicated moderate linear
relationships (judged by R2). Twenty-five percent and 45% of the
observed variations in EQ-5D score could be described by a linear
model with 15D or SF-6D index score as the explanatory variable,
and 33% of the variation in 15D could be described by a linear
model with SF-6D index as the explanatory variable.
The QALE estimates produced by the three instruments are
shown inTable 4.With the EQ-5D, a 30-year-old patientwith RAwho
is assumed to have similar survival probabilities as the general pop-
ulation would be expected to achieve 39.4 QALYs until age 79 years.
Using similar assumptions, the 30-year-old patient would expect to
achieve 45.6 QALYs with the 15D instrument and 37.9 QALYs with
the SF-6D. The 15D instrument thus provides 6.2 QALYs more than
the EQ-5D, and the SF-6D instrument provides 1.5 QALYs less.
In the gender-stratified analysis where the index scores were
estimated separately for men and women and the survival prob-
ability was the average for the Danish population, a 30-year-old
male patient would be expected to achieve 2.4 more QALYs than a
womanwith the EQ-5D, 1.8more QALYswith the 15D, and 2.0more
QALYs with the SF-6D. Using the clinical indicator for disease status
(CRP), patients with high CRP levels might expect 4.3 fewer QALYs
thanpatientswithnormal CRP levels using the EQ-5Dand1.8 and 2.5
fewer QALYs with 15D and SF-6D, respectively.
Fig. 2 – Correlation between index scores of different
instruments (n=2500).
Table 4 – Estimated quality-adjusted life expectancies usin
old patient with rheumatoid arthritis until age 79 years (95
n EQ-5D
QALY CI
Whole sample 2500 39.4 (38.9–40)
Men 636 41.3 (40.1–42.6)
Women 1864 38.9 (38.3–39.5)
Normal CRP 1778 40.6 (40–41.2)
High CRP 722 36.3 (35.1–37.5)
HAQ  1 1428 40.0 (39.5–40.7)
HAQ  1–2 523 32.5 (31.1–33.8)
HAQ  2 132 26.7 (23.4–30)
DAS28  2.6 981 44.4 (43.7–45)
DAS28  2.6 1519 36.3 (35.7–37.1)
CI, confidence interval; CRP, C-reactive protein; DAS28, Disease Acti
five-dimensional (EQ-5D) questionnaire; HAQ, Health Assessment Qu
SF-36).All three instruments indicated large differences in QALE for
patients in the three functional disability groups (HAQ score). The
difference between the nonimpaired patients and the moderately
impaired patients was 7.5 QALYs with EQ-5D, and 5.8 QALYs be-
tween the moderately and severely impaired patients. The differ-
ence in QALE using the 15D was about half that of the EQ-5D (3.3
and 2.4 QALYs, respectively), while the SF-6D provided differences
of 5.7 and 3.6 QALYs. Compared with patients with active disease,
the QALE for patients in remission was 8.0 QALYs higher when
using the EQ-5D, 3.9 QALYs higher when using the 15D, and 5.9
QALYs higher when using the SF-6D.
As a sensitivity analysis we conducted the analysis excluding
the 860 respondents who did not fully complete the three ques-
tionnaires. Themean EQ-5D scoreswere elevated by 0.010, the 15D
by 0.041, and the SF-6D by 0.015. The QALE estimated with EQ-5D
consequently increased by 0.4 QALY, with the 15D by 1.9 QALY,
andwith the SF-6D by 0.6 QALY. This corresponds to an increase of
1.0%, 4.2%, and 1.5%, respectively, in QALE.
Discussion
The average index scores from the three instruments differed by
more than 0.13 on a 0 to 1 scale, corresponding to nearly 20% of the
lowest score. Such lack of agreement between the instruments
has been found in other studies. An Australian study compared
mean scores estimated for 996 individuals who completed the
same three instruments [35]. In contrast to our findings, the SF-6D
provided consistently higher scores than did 15D and EQ-5D in
different age groups and in community, outpatient, and inpatient
samples. Similarly, a British study reported thatmean SF-6D index
scores were consistently higher than mean EQ-5D scores [36]. In
both these studies, SF-6D scores were derived from the SF-36 in-
strument. More similar to our study, an Italian study of 1011 pa-
tients attending 16 general practices reported average SF-6D index
scores that were lower than EQ-5D scores (0.70; SD 0.11 and 0.80;
SD 0.20, respectively) [37]. A Canadian study of 313 patients with
RA also reported higher mean index scores on EQ-5D than on
SF-6D [38]. The difference between the studies might be due to
different scoring algorithms for different language versions of the
same instrument, although close inspection of the articles could
not firmly establish that this was the case.
Only a few studies have compared all three instruments to-
gether. The previous-mentioned Australian study reported 15D
scores higher than EQ-5D scores [35], and a Norwegian compari-
ree different generic instruments, modeled for a 30-year-
insky–Robb CI).
15D SF-6D
QALY CI QALY CI
45.6 (45.2–45.9) 37.9 (37.5–38.4)
47.0 (46.1–47.8) 39.5 (38.4–40.7)
45.2 (44.8–45.6) 37.5 (37–37.9)
46.1 (45.7–46.5) 38.6 (38.1–39.2)
44.3 (43.6–45) 36.1 (35.2–37)
45.5 (45.1–45.9) 38.2 (37.6–38.7)
42.2 (41.4–43) 32.5 (31.6–33.5)
39.8 (38.4–41.1) 28.9 (27.5–30.4)
48.0 (47.4–48.6) 41.5 (40.9–42.2)
44.1 (43.6–44.5) 35.7 (35.1–36.2)
core that involves clinical assessment of 28 joints; EQ-5D, EuroQol
nnaire; SF-6D, six-dimensional health state short form (derived fromg th
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338 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 3 4 – 3 3 9son using patients with HIV/AIDS found that the index score on
15D was 11% higher than that from the EQ-5D, while the SF-6D
index score was 6% lower than the EQ-5D score [39]. A Greek study
of 319 individuals with type 2 diabetes also compared the mean
scores from the three instruments and showed higher mean
scores for 15D than for EQ-5D and lower mean scores for SF-6D
[40]. These findings are broadly similar to ours. Another recent
Norwegian study using 1041 patients with RA, however, found
that the average score of 15Dwas 35% higher than the EQ-5D score
and the SF-6D score was 7% higher than the EQ-5D score [41]. Also,
a Greek study comparing scores of 48 patients with cancer in che-
motherapy found that both 15D and SF-6D mean scores were
higher than the mean EQ-5D scores [42]. These differences in
mean scores between instruments were more profound than in
our sample and in contrast to our study the SF-6D provided higher
average scores than did the EQ-5D.
While the three HRQoL instruments measure broadly similar
dimensions of HRQoL (e.g., physical function, pain, psychological
state, social function), they assess these dimensions in varying
amount of detail and with different emphasis by way of quite
different scoring systems. It might thus be unreasonable to expect
that they provide similar index scores. The disagreement between
instruments appears to be most pronounced for patients with
poor health and severe disability, whichmight be one explanation
of the large variation in mean scores observed in the Norwegian
and Greek studies.
Paired t-tests showed that themean health status score for the
sample was statistically significantly different on the three instru-
ments (mean scores 0.72, 0.83, and 0.69 on EQ-5D, 15D, and SF-6D,
respectively). The health states with low scores, however, were
reported quite differently. The 25 individuals with the lowest
scores (individuals within the lower one percentile scores) re-
ported health states with scores ranging from 0.162 to 0.624 on
the EQ-5D, from 0.525 to 0.428 on the 15D, and from 0.411 to
0.345 on the SF-6D. One of the explanations for this wide varia-
tion at the lower end of the scoring scale is probably that the
EQ-5D scoring algorithm was based on data where the respon-
dent could assess whether a particular health state was better
or worse than death; health states worse than death are scored
with a negative value. In the design of the scoring algorithm of
the two other instruments, no health states were able to be
valued worse than death.
Other methodological explanations might also cause the wide
difference in health state valuations for individuals. For example,
the methodology with which the valuation data has been ob-
tained. The Danish scoring exercise was based on data obtained
from time-trade off exercises where respondents were asked to
provide valuation of specific health states defined by the EQ-5D
[26]. The 15D scoring was based on multiattribute utility theory
where respondents first were asked to provide visual analogue
data of the 15 dimensions and second to provide visual analogue
data of the value of the five levels within each dimension [43].
These two sets of valuations were combined by using the princi-
ples ofmultiattribute utility theory to a single valuation score. The
scoring algorithm of the SF-6D was based on data obtained
through standard gamble exercises to provide valuation of speci-
fied health states defined by the SF-6D [44]. There might thus be
methodological explanations for the observed differences be-
tween instruments. Choice of HRQoL measure based on clinical
relevance, however, is difficult because the three instruments ap-
pear to have acceptable correlation with arthritis-specific mea-
sures but varying degree of responsiveness to changes in disease
state over time (e.g. [14,45]).
Given that there is wide variation in the index score generated
fromdifferent instruments, it is relevant to assess the consequences
of such variation on the estimation of QALE. Our results have shown
that with data from the 15D instrument a 30-year-old patient mightexpect nearly 6 QALYs more than if the assessment was based on
EQ-5D data. If the assessment was based on the SF-6D data, the 30-
year-old patient could expect 1.6 fewerQALYs than if itwas based on
EQ-5D data. Such large discrepancies in health outcomes are of con-
cern for the comparability of economic evaluations.
In an earlier article we have shown that patients with RA have
considerably lower EQ-5D index scores than a similar age- and gen-
der-matched general population [46,47].We found that patientswith
RA in remissionhadhigher indexscores thandidpatientswithactive
RA and that patients with RA in remission scored 0.12 to 0.15 lower
than the general population. The disease is thus associated with a
considerable loss in HRQoL. Using the EQ-5D data for the RA sample
population, QALEwas estimated at 39.4 QALYswhile similar data for
the general population (n 7967) estimated QALE at 47.4 QALYs. If it
is assumed that RA has no impact on mortality, this would indicate
that RA disease is potentially associated with a QALE loss of about 8
QALYs purely associatedwith loss of HRQoL. However, untreated RA
is also associated with increased mortality risk, and the potential
QALE loss might therefore be underestimated. Judging by the sub-
groupanalysis, patientswith severeRAmight experience even larger
loss of QALE.
Economic evaluations compare patient outcomes for different
patient groups. As our results show that the choice of outcome in-
strumentmaywell influence the results, a comparison of cost-effec-
tiveness ratios should only be done when the same instrument and
scoring algorithmhave been applied. A recent study has shownhow
the incremental cost-effectiveness ratio might lead to different rec-
ommendations if the QALY measurement was based on EQ-5D or
SF-6Ddata [48]. The results fromour study should raise awareness of
the methodological challenges that emerge when comparing cost-
effectiveness ratios from studies that use different preference-based
health outcome instruments.
Our analysiswas static in nature and applied the perspective of
a statistical person aged 30 years. Through statistical analysis, we
have modeled the survival and changes in HRQoL in different age
groups as observed in the cross-sectional sample. This approach is
frequently used in epidemiological research where a difference in
life expectancies is observed, for example, for smokers and non-
smokers [3], or for other risk factors such as high alcohol intake,
low physical activity, and poor dietary habits [49]. If we had not
made the adjustment for quality of life andhadused observational
death data for patients with RA, we would indeed have used iden-
tical methods andmight have been able to estimate life expectan-
cies for different subgroups. However, in economic evaluations,
improvements in life expectancies are not considered as the only
worthwhile objective for health interventions—the quality of life
during the lifetime is also considered important. Our study has
shown that measures of quality of life can easily be incorporated
in the epidemiological method by applying age- and gender-spe-
cific averages for HRQoL in the calculation of QALEs.
The strength of our static approach is that we made comparisons
where the only change was the outcome instrument and kept every-
thing else unchanged. In this way, we also disregarded differences in
mortality risk related to age and gender. Such static analyses are to a
large extent artificial, and we would recommend not interpreting the
calculated life expectancies as truedescriptors for lives of patientswith
RAbutratherasstatisticalmodels.Formostpatients, thesecalculations
would not realistically reflect their life expectancy, and more realistic
descriptionscouldbeachievedthroughclinical trials.Thegreatstrength
of the static analytical approach, however, is that it can identify factors
thatmight influence suchmeasurements in clinical trials.
In our calculations of QALE, we had no data that enabled us to
take into account the statistical uncertainty in the QALEs. We em-
ployed a less known method (Krinsky–Robbs procedure) that has
been developed to produce estimates for standard deviations inwill-
ingness-to-pay estimates. The procedure uses the estimated param-
eters (meanandcovariances) from the regressionandahighnumber
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339V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 3 4 – 3 3 9of sampling from a multinomial distribution. When we base the
QALEcalculationson these samples, it becomespossible to construct
nonparametric 95%confidence intervals for themeanestimates. It is,
however, surprising that the confidence intervals are verynarrow for
the mean estimates of the whole population.
In conclusion, this study has illustrated the consequences of us-
ing different HRQoL instruments in the calculation of QALE and has
shown that the choice of instrument appears to influence both the
absolute level and the incremental change inQALE. Theseare impor-
tant considerations when results of different economic analyses are
compared. The consequence must be that unless the QALE calcula-
tions are made with the same tools (instruments and scoring algo-
rithms), the results will not be directly comparable.
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